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Abstract
Giant cell myocarditis is a rare but often devastating diagnosis. Advances in cardiac imaging and mechanical circulatory support
have led to earlier and more frequent diagnoses and successful management. This disease state has wide variation in acuity of
presentation, and consequently, optimal treatment ranging from intensity and type of immunosuppression to mechanical cir-
culatory support is not well defined. The following case describes the management of a patient with an unusual presentation
of giant cell myocarditis over a 10 year course of advanced heart failure therapies and immunomodulatory support. This case
highlights emerging concepts in the management of giant cell myocarditis including sub-acute presentations, challenges in di-
agnosis, and treatment modalities in the modern era.
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Introduction
Giant cell myocarditis (GCM) is a rare, incompletely under-
stood disease. Severe, rapidly progressive heart failure in
young to middle-aged adults characterizes the most fre-
quently reported presentation of GCM.1 Prognostic differ-
ences have been suggested on the basis of initial
presentation of myocarditis, with patients in fulminant myo-
carditis and histologically proven GCM both highly associated
with short-term mortality.2 Early reports of GCM demon-
strated survival rates around 5 1/2 months after diagnosis;
however, modern reports have shown 5 year survival free
from death or heart transplant of 52–72% with immunosup-
pression.3–5 Some patients respond to immunosuppression;
many require transplantation for long-term survival.4 In-
creased use of mechanical circulatory support (MCS) over
the past decade has played a pivotal role in improving sur-
vival and time to transplant. The optimal balance between
immunosuppression, MCS, and heart transplant has not been
fully elucidated in GCM. The following case describes an
atypical presentation of GCM managed with a combination
of immunosuppression, left ventricular assist device (LVAD),
and eventually orthotopic heart transplantation (OHT).
Case report
A 54-year-old Caucasian woman presented with symptoms of
chest tightness, palpitations, and non-sustained ventricular
tachycardia (VT). Her past medical history was significant for
supraventricular tachycardia; she took no prescription medi-
cations and lived in an area with high prevalence of tick-
borne illnesses. Cardiovascular family history included heart
failure (mother) and supraventricular tachycardia (daughter).
Her physical examination was notable for clear lungs and no
jugular venous distension, gallops, or murmurs. Vitals in-
cluded a heart rate of 68 beats per minute, blood pressure
of 100/60 mmHg, height of 64 inches, and weight of 62.5
kg. Her admission electrocardiogram showed biventricular
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bigeminy and Q waves in leads V1 and V2. Her labs were nor-
mal except for B-type natriuretic peptide of 237 pg/mL (refer-
ence range < 100 pg/mL) and troponin I 0.16 ng/mL
(reference range < 0.08 ng/mL). Transthoracic echocardio-
gram demonstrated normal biventricular function, mild mitral
regurgitation, mild pulmonary hypertension, and an esti-
mated left ventricular ejection fraction (LVEF) of 60%. Coro-
nary angiography revealed no coronary disease, and she
was discharged on metoprolol, lisinopril, and mexiletine.
She was admitted three times the following year for VT
with persistently elevated troponin levels (0.12–0.42
ng/mL). Her LVEF had declined to 30–35%, and a dual cham-
ber implantable cardioverter-defibrillator was implanted.
Cardiac magnetic resonance imaging found subepicardial
hyper-enhancement along the mid-anterior wall of the left
ventricle compatible with myocarditis and LVEF of 32.8%
(Figure 1). Her metoprolol was increased on discharge.
She was referred to an academic medical center for
endomyocardial biopsy, which showed inflammatory findings
thought to be most consistent with Lyme carditis, staining for
amyloid was unrevealing (Figure 2). Serologies for Lyme dis-
ease were negative. Treatment consisted of doxycycline, cor-
ticosteroid taper, and mycophenolate mofetil. A depiction of
pharmacological therapy received during the patient’s course
is summarized in Figure 3. She had gradual improvement in
LVEF that correlated with corticosteroid treatment and de-
clined when corticosteroids were stopped. Despite treat-
ment, her clinical status declined with recurrent heart
failure admissions requiring inotropes, inability to tolerate
evidence-based medical therapy, worsening LVEF, and recur-
rent VT, leading to consideration of advanced heart failure
therapies.
Two years after initial presentation, a HeartMate II LVAD
(Thoratec, Pleasanton, CA) was implanted as a bridge to
Figure 1 Cardiac magnetic resonance imaging. (A) Mid short axis late gadolinium enhancement (LGE) image. (B) Two-chamber LGE image. There is a
distinctive pattern of diffusely located “patchy” transmural delayed hyper-enhancement compatible with infiltrative cardiomyopathy and fibrosis of the
left ventricle. This pattern is not indicative of ischaemic cardiomyopathy. There is subepicardial LGE along the mid-anterior wall, which can be seen in
myocarditis.
Figure 2 Endomyocardial biopsy. (A) High-power hematoxyylin and eosin (H&E) stained image showing markedly damaged myocardium with
intermyocyte fibrosis and a diffuse infiltrate of lymphocytes. (B) High-power H&E stained image showing a capillary surrounded with lymphocytic in-
filtrate. (C) Low power H&E stained image showing endocardium with a predominantly lymphocytic infiltrate. Black arrows indicate lymphocytic infil-
trate and white arrows indicate damaged myocardium.
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transplant. Left ventricular apex core biopsy demonstrated a
focal chronic lymphocytic infiltrate notable for multiple multi-
nucleated cells and absence of granulomas, consistent with
GCM (Figure 4). Additionally, staining for mycobacteria, atyp-
ical mycobacteria, bacteria, and fungi was negative. After
LVAD implantation, she restarted mycophenolate mofetil for
approximately 1 year, transitioned to azathioprine for a few
days, and then antimetabolites were withdrawn because of
leukopenia. Time to transplant was prolonged because of
the presence of high levels of preformed antibodies. She re-
ceived antibody reduction therapy with rituximab and intra-
venous immunoglobulin 4 months following LVAD implant;
plasma exchange was added 4 months later because of
persistently high levels of preformed antibodies. During this
time, she experienced an improvement in symptoms and left
ventricular function; however, she was unable to tolerate a
trial wean of LVAD support to 8400 rpm, with a VO2 max of
10 mL/kg/min and peak respiratory exchange ratio of 1.3.
More aggressive immunosuppression regimens targeting
GCM were ultimately not pursued because of infection risk.
A suitable donor with negative prospective crossmatch be-
came available, and she underwent an OHT at age 60. Her in-
duction immunosuppression included three doses of rabbit
anti-thymocyte globulin, methylprednisolone 1 g followed
by 250 mg every 8 h for six doses, and mycophenolate 1 g in-
traoperatively followed by 1 g twice/day. Maintenance
Figure 4 Left ventricular apex core biopsy. Both views are high-power hematoxyylin and eosin (H&E) stained images showing markedly damaged
myocytes with a lymphocytic infiltrate with the addition of multinucleated giant cells, not associated with granulomas. Black arrows indicate lympho-
cytic infiltrate, white arrows represent necrotic myocardium, and giant cells are circled in black.
Figure 3 Timeline of case report showing LVEF over the 10 year follow-up, treatment regimens, and time of LVAD and OHT relative to initial presen-
tation. ATG, anti-thymocyte globulin; IVIG, intravenous immunoglobulin; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction;
PLEX, plasmapheresis; QOD, every other day.
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immunosuppression included tacrolimus, prednisone, and
mycophenolate. She is now 4 years post-transplant, doing
well without cellular or antibody-mediated rejection or evi-
dence of recurrent GCM.
Discussion
Classic reports of GCM include patients with acute onset
heart failure rapidly progressing to cardiogenic shock and
death within weeks to months of initial presentation.4,6–8
GCM is often associated with refractory ventricular arrhyth-
mias or other conduction abnormalities.4,7,9,10 Only 14–29%
of patients initially present with VT compared with more than
75% of patients presenting with acutely decompensated
heart failure.1 These figures are likely a reflection of historical
findings when GCM was only identified at the time of au-
topsy. A change in the acuity of patients diagnosed with
GCM may be seen with increasing utilization of prospective
endomyocardial biopsy and apex biopsy at the time of LVAD
implantation. This sub-acute case managed with immunosup-
pression and LVAD, followed by OHT with no GCM recurrence
after 4 years, likely represents an example of possible benefit
of early GCM diagnosis.
Diagnosis of GCM is often challenging because of the focal
nature of the disease and similarities with other infiltrative
cardiomyopathies; this is demonstrated in our patient who
had definitive evidence of GCM only after left ventricular
apex biopsy. Prospective endomyocardial biopsy has been
the gold standard for the diagnosis of GCM since the 1980s
because of the similarity in clinical features with other etiolo-
gies of myocarditis, particularly sarcoidosis, with the caveat
that repeat biopsies are often necessary.1,5 Targeted biopsies
based on the findings of cardiac magnetic resonance imaging
and other imaging studies may lead to increased diagnosistic
accuracy of initial endomyocardial biopsy. The pathologic
diagnosis of GCM requires exclusion of other causes of myo-
carditis including infectious diseases, amyloidosis, and sar-
coidosis. GCM pathophysiology is linked to a T-cell-mediated
process, characterized by infiltration of cardiomyocytes by
lymphocytes, histocytes, multinucleated giant cells, eosino-
phils with necrosis of cardiomyocytes, and notable absence
of granulomas.1,4,11–13
Saltykow first described GCM in 1905, and the role of im-
munosuppression was reported in 1987.14,15 There are no
prospective clinical trials to guide management of this rare
disease; however, retrospective reports and case series
suggest maintenance immunosuppressive therapy with or
without induction. Induction regimens may include high dose
steroids, muromonab CD3, or ATG, while maintenance
therapy typically includes a corticosteroid, antimetabolite,
and calcineurin inhibitor.4,16 Survival beyond 1 year after
diagnosis of GCM is rare without treatment; however, use
of immunosuppression has been associated with extended
survival.3,4 Choosing an optimal evidence-based immunosup-
pression regimen is challenging because of overall paucity of
evidence because of the small number of reports and ab-
sence of data from randomized clinical trials. On the other
hand, descriptions of successful use of MCS in patients with
GCM have followed the increasing use of this modality in
heart failure.17–19 Antibody reduction therapy with mycophe-
nolate, rituximab, intravenous immunoglobulin, and plasma
exchange coincided with improvement in our patient’s symp-
toms and cardiac function, which offers an area for future
study as T cells are traditionally thought to be the main
GCM etiology.
Goals of GCM treatment have been to control symptoms,
prolong life, and delay transplant. Heart transplantation is
not necessarily a curative treatment, with approximately
20–25% of patients experiencing recurrence.3,20 There may
be a prognostic difference between symptomatic and asymp-
tomatic biopsy proven recurrence and consequently manage-
ment of each may vary.17 Fortunately, our patient has not
had recurrence to date. Contemporary reports on survival in
GCM have described survival after OHT at 1, 5, and 10 years
as similar to other forms of myocarditis (94%, 82%, and 68%;
P = 0.11). 21 Our patient highlights an example of an uncom-
plicated post-transplant course after GCM diagnosis.
Conclusions
Advances in diagnostic modalities and treatment options are
leading to earlier diagnosis and improved outcomes in GCM.
Rare diseases are challenging to study with prospective clini-
cal trials and clinicians often seek retrospective reports for
guidance; registry data have filled this void in other uncom-
mon conditions and may be beneficial in GCM. This case dem-
onstrates a slowly progressive course, requiring durable MCS
2 years after presentation at which time the diagnosis of
GCM was made. Intriguingly, cardiac function improved dur-
ing antibody reduction therapy, though MCS could not be
weaned and OHT was ultimately pursued. This suggests an
area for further research into alternative methods to treat
GCM. This case provides considerations for the utilization of
synergistic imaging and treatment modalities for patients
with GCM in order to promote early identification and ulti-
mately reduce symptoms and improve functional status.
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